![]() |
|
|
Vol. 61, Issue 3, 595-605, March 2002
Molecular Neurobiology Laboratory, the Salk Institute, La Jolla, California (B.V., S.F.H.); and the Vollum Institute, Oregon Health and Science University, Portland, Oregon (J.J.K., G.L.W.)
| |
Abstract |
|---|
|
|
|---|
At central excitatory synapses, the transient elevation of
intracellular calcium reduces
N-methyl-D-aspartate (NMDA) receptor activity. Such `calcium-dependent inactivation' is mediated by interactions of calcium/calmodulin and
-actinin with the C terminus of NMDA receptor 1 (NR1) subunit. However, inactivation is also NR2-subunit specific, because it occurs in NR2A- but not
NR2C-containing receptors. We examined the molecular basis for
NR2-subunit specificity using chimeric and mutated NMDA receptor
subunits expressed in HEK293 cells. We report that the intracellular
loop immediately distal to the pore-forming P-loop M2 (M2-3 loop), as
well as a short region in the C terminus, are involved in NR2-subunit
specificity. Within the M2-3 loop, substitution of residue 619 in NR2A
(valine) for the corresponding NR2C residue (isoleucine) reduced
inactivation without affecting calcium permeability of the channel. In
contrast, a Q620E mutation in NR2A reduced the relative calcium
permeability without altering inactivation. Mutation of three
serine/threonine residues in the M2-3 loop also reduced inactivation,
as did substitution of the intracellular C terminus of NR2A for NR2C.
We speculate that the M2-3 loop of NR2 modulates calcium-dependent
inactivation by interacting with the NR1 C terminus, a region known to
be essential for inactivation.
| |
Introduction |
|---|
|
|
|---|
NMDA
receptors are heteromers of NMDA receptor 1 (NR1), NR2, and, in some
cases, NR3 subunits. Several characteristics of native NMDA channels,
including magnesium sensitivity, glycine affinity, and desensitization,
depend on both NR1 and NR2 (for review see McBain and Mayer, 1994
;
Dingledine et al., 1999
). The molecular mechanisms responsible for
NR2-subunit specific differences in receptor function are complex and
not well characterized. For example, block by magnesium ions is largely
determined by residues in the NR2 pore domain (M2) (Burnashev et al.,
1992
; Mori et al., 1992
; Sakurada et al., 1993
; Williams et al., 1998
;
Wollmuth et al., 1998
), but regions outside of M2 are modulatory (Kuner
and Schoepfer, 1996
). Likewise, calcium-dependent inactivation
(Legendre et al., 1993
; Rosenmund and Westbrook, 1993
) also depends on
NR1 and NR2. Whereas the interactions of two intracellular proteins, calcium/calmodulin (Ehlers et al., 1996
) and
-actinin (Wyszynski et
al., 1997
), with the C-terminal region of NR1 are necessary for
inactivation (Zhang et al., 1998
; Krupp et al., 1999
), the coexpressed
NR2 subunit is permissive (Krupp et al., 1996
). This effect of the
NR2-subunit is not caused by the small differences in the calcium
permeability between the different NR1/NR2 heteromers (Krupp et al.,
1996
), suggesting that domains within NR2 influence inactivation.
To determine domains in NR2 that influence inactivation, we expressed NR1/NR2 heteromers in HEK293 cells. We found that the valine residue at position 619 in the M2-3 loop of NR2A is critical for NR2 subunit specificity. A point mutation that switched this residue in NR2A (valine) for NR2C (isoleucine) reduced inactivation without affecting calcium permeability. Mutagenesis of serine/threonine residues in the M2-3 loop of NR2 also affected inactivation. In addition, the proximal portion of the intracellular NR2 C terminus had a small modulatory effect.
| |
Materials and Methods |
|---|
|
|
|---|
Molecular Biology.
The following NMDA subunit cDNAs were
used: NR1-1a (GenBank accession number U08261), NR1-4a
(GenBank accession number U08267) (Hollmann et al., 1993
), NR2A
(GenBank accession number D13211), and NR2C (GenBank accession number
D13212) (Ishii et al., 1993
). Most NR2A/2C chimeras have been described
previously (Krupp et al., 1998
), except for
2C2+iA
(NR2CM1-I630AQ620-V1464), 2C2+iiA
(NR2CM1-E631AN621-V1464),
and 2C3A
(NR2CM1-L643AV633-V1464). Chimeras and mutants were generated using the strategy of gene splicing
by overlap extension polymerase chain reaction (Horten et al., 1989
)
using Pfu polymerase (Stratagene, La Jolla, CA). All NMDA
subunit cDNAs and chimeras were cloned into pCDNA1/amp (Invitrogen,
Carlsbad, CA). Truncation mutants were generated by introduction of a
stop codon at the appropriate position. Amino acid numbers for
mutations in wild-type subunits are as given in Ishii et al. (1993)
.
For mutations in chimeras, we used the amino acid numbering of the
embedding wild-type subunit. All clones were confirmed by restriction
analysis and sequence analysis. To identify cells expressing NMDA
receptors, HEK293 cells were cotransfected with cDNA coding for the
lymphocyte CD4 receptor. The CD4 cDNA, kindly provided by Dr. John
Adelman (Vollum Institute, Portland, OR), was inserted into the JPA
vector. For detection of successfully transfected cells, 1 µl of
Dynabeads M-450 CD4 (Dynal, Norway) was added in 1 ml of medium to each
35-mm dish. The dish was then gently swirled for 15 to 20 min before recording.
Transfection and Handling of HEK293 cells. HEK293 cells were plated 6 to 12 h before transfection in Dulbecco's modified Eagle's medium plus 10% fetal calf serum (Hyclone, Logan, UT), 1% glutamine (Invitrogen), and 1% penicillin-streptomycin (Invitrogen; 37°C, 5% CO2). Cells were plated on 31-mm polylysine-coated glass coverslips placed in 35-mm dishes. The cDNAs for NR1/NR2/CD4 were mixed in a 4:4:1 ratio and added to HEK293 cells as a calcium-phosphate complex (Calcium Phosphate Transfection System; Invitrogen). Kynurenic acid (3 mM; Sigma, St. Louis, MO) and D,L-2-amino-5-phosphonopentanoic acid (1 mM; Tocris Cookson, St. Louis, MO) were routinely added to prevent NMDA receptor-mediated excitotoxic cell death. The transfection mixture was removed after 12 to 18 h by exchanging with fresh culture medium containing kynurenic acid and D,L-2-amino-5-phosphonopentanoic acid. 5'-Fluoro-2-deoxyuridine (0.2 mg/ml) and 0.5 mg/ml uridine (Sigma) was added to inhibit cell proliferation.
Recording, Solutions, and Drug Application.
Whole-cell
voltage-clamp recordings were performed 12 to 48 h after
transfection. The recording chamber was continuously superfused at room
temperature (~ 20-22°C) with an extracellular solution: 162 mM
NaCl, 2.4 mM KCl, 10 mM HEPES, 10 mM dextrose, and 1 mM CaCl2, pH 7.25 (NaOH), 325 mOsm.
High-performance liquid chromatography-grade water was used to avoid
contaminating amounts of glycine or other amino acids. Patch pipettes
were pulled from thin-walled borosilicate glass (TW150F-6; World
Precision Instruments, New Haven, CT) and had resistances between 2 and
5 M
. The intracellular solution included an ATP-regenerating system:
115.5 mM CsCH4SO3, 10 mM HEPES, 6 mM MgCl2, 4 mM
Na2ATP, 20 mM phosphocreatine, 500 U/ml creatine
phosphokinase, 0.1 mM leupeptin, and 0.1 mM EGTA, pH 7.2 (CsOH), 320 mOsm (sucrose). Patch solutions were prepared daily from frozen stocks
and kept on ice until use. Data were acquired using pClamp6 software in
combination with an Axopatch-1B amplifier (Axon Instruments, Union
City, CA). The membrane voltage was clamped at
50 mV unless otherwise
indicated. Currents were low-pass filtered at 0.2 kHz and digitized at
1 kHz. Series resistance was routinely compensated (60 to 90%). Cell
input resistances (range, 400-3000 M
) were continuously monitored by
a short
10 mV voltage step just before each agonist application.
-D-ribofuranosylbenzimidazole (DRB;
ethanol [1:2,000 final ethanol-dilution]; Calbiochem) were added to
bath and agonist-containing solution at least 15 min before recording.
Data Analysis and Statistics.
The extent of
inactivation was measured as the percentage reduction in current
amplitude at the end of the 5-s application compared with its initial
peak (see Legendre et al., 1993
). The onset of inactivation was
evaluated by fitting a monoexponential function with the time constant
. This provided satisfactory fits in most cases. However, responses
from some mutants had variable kinetics, including biphasic
inactivation with a very slow second component. This slow component was
often too slow (
> 5 s) to be fitted in a meaningful way
during a 5-s agonist application. For such mutants, we calculated time
constants only for responses that could be adequately fitted by a
monoexponential function. Responses with less than 15% inactivation
were not fitted. We analyzed responses obtained during the first 5 min
after whole-cell access.
| |
Results |
|---|
|
|
|---|
Molecular Determinants for the NR2-Subunit Specificity of
Calcium-Dependent Inactivation.
Calcium-dependent inactivation is
NR2-subunit specific (Krupp et al., 1996
). During long (5 s) whole-cell
applications of NMDA in 2 mM extracellular
Ca2+, responses from NR1-1a/2A heteromers
showed prominent inactivation that reached steady-state by the end of
the application (Fig. 1B, top trace). The
onset of inactivation could usually be adequately described by a
monoexponential fit (47.6 ± 2.6%; n = 28;
= 2.1 ± 0.3 s; n = 22). In
contrast, NR1-1a/2C responses did not inactivate (
3.5 ± 2.3%;
n = 5; Fig. 1B, bottom trace). To explore the molecular basis of this NR2 specificity, we constructed a series of chimeras in
which progressively larger segments of NR2A were exchanged for NR2C
(Fig. 1). The N terminus of the NR2 subunit controls one form of NMDA
receptor desensitization, glycine-independent desensitization (Krupp et
al., 1998
; Villaroel et al., 1998
). Because the chimeras contained the
N terminus of the nondesensitizing NR2C subunit, we were able to use
saturating concentrations of agonist (1 mM NMDA or glutamate). Thus the
relaxation in the chimeras exclusively reflects inactivation.
|
= 2.1 ± 0.3 s;
n = 5) nor the additional exchange of the first
transmembrane region (M1) in NR2A for NR2C (2C1A;
41.7 ± 6.4%;
= 2.2 ± 0.5 s;
n = 4) affected inactivation. A chimera in which the
switch from NR2A to NR2C was at the end of M2
(2C2A;
= 2.1 ± 0.2 s; n = 6) also showed normal inactivation (Fig. 1B).
However, the exchange of one additional residue in the intracellular
loop distal to M2 (2C2+iA; Fig. 1) markedly
reduced inactivation (25.5 ± 4.7%, n = 11). The
exchange of the subsequent NR2A residue (chimera 2C2+iiA) or a switch from the NR2C to the NR2A
sequence at the end of the third membrane region
(2C3A) had no additional effect, suggesting that
the proximal M2-3 loop is a determinant of inactivation. Furthermore,
exchange of this region also influenced the kinetics of inactivation,
which became highly variable. In chimera 2C2+iA,
8 of 11 cells had inactivation that was biphasic or too small to be
fitted (Fig. 1B). Onsets in the remaining three cells were
monoexponential (
= 1.6 ± 0.6 s), similar to NR2A. Three of four cells expressing chimera 2C2+iiA
and four of eight cells expressing chimera 2C3A
also had biphasic inactivation. The onset of inactivation in the other
cells was monoexponential with time constants of
= 1.8 s (n = 1; 2C2+iiA) and
= 1.6 ± 0.6 s (n = 4;
2C3A). These values were not significantly different from those of NR2A. In all chimeras, the current relaxations were caused by calcium-dependent inactivation, because they were abolished in calcium-free solution or when the chimeras were
cotransfected with NR1stop838 (not shown), which
lacks the C0 domain essential for inactivation (Zhang et al., 1998
= 1.8 ± 0.2 s;
n = 5; monoexponential decay in all cells), suggesting
that this effect was indirect, perhaps through the spatial arrangements
of M3, M4, and/or the M2-3 loop with respect to the channel pore.
Finally, the difference between 2C4A and 2C
suggests that M4 or the intracellular C terminus of NR2 has a small
effect on inactivation. Consistent with this interpretation, 2A4C, the reverse chimera to
2C4A, had reduced inactivation (32.9 ± 3.9%;
= 2.3 ± 0.6 s; n = 7;
monoexponential decay in all cells) compared with NR2A. Based on the
results with these chimeras, we examined the role of the M2-3 loop and
the C terminus using site-directed mutagenesis.
NR2A Positions 619 and 620 Differentially Affect Inactivation and
Calcium Permeability.
The chimeras indicate that the first residue
immediately distal to M2 affects inactivation. Consistent with this
observation, a mutation of valine 619 in NR2A to the corresponding
isoleucine in NR2C reduced inactivation (33.9 ± 4.9%;
n = 12) to a similar degree as chimera
2C2+iA (Fig. 2A).
We also examined other neutral amino acid exchanges at position 619. A
V619A mutation did not reduce inactivation (53.1 ± 2.3%;
n = 5), whereas V619F and V619W mutations did (Fig.
2B). Mutation of the immediately adjacent residue 620 (glutamine) to
the corresponding NR2C residue (glutamate) did not change inactivation
(Fig. 2C).
|
|
Mutation of Serine/Threonine Residues in the M2-3 Loop of NR2
Affects Inactivation.
Residues 619 and 620 are immediately
C-terminal to the pore-forming M2-region and thus could have
nonspecific effects on pore architecture. Because nonspecific
perturbations might also be expected from the exchange of charged
residues in other regions close to the cytoplasmic face of the pore, we
individually mutated other negatively charged residues in the
intracellular loops of NR1 and NR2A. None of the mutations in NR1
significantly affected inactivation, including alanine substitutions of
four serine residues (Fig. 4, A and B).
Likewise, neither the neutralization of three sequential glutamic acids
immediately before M2 nor their charge inversion affected inactivation
(Fig. 4, A and B). Inactivation was also unaffected by phenylalanine
substitutions of two tyrosines in the M1-2 loop of NR2 (Fig. 4C). In
contrast, there was a significant reduction of inactivation when three
adjacent serine/threonine residues in the M2-3 loop of NR2 were
mutated to alanine (NR2A(TTS625-7A): 23.7 ± 5.1%; n = 11; Fig. 4D). A similar reduction was
observed when any two of these three residues were mutated to alanine. Single point mutations of these residues did not reduce inactivation (Fig. 4D). The reduced inactivation with
NR1-1a/2A(TTS625-7A) was not caused by
decreased calcium permeability (pCa/pCs: 6.0 ± 1.0;
n = 4).
|
|
The NR2 C Terminus Affects Calcium-Dependent Inactivation.
We
addressed the potential role of the NR2 C terminus in inactivation
using a series of C-terminal truncations in NR2A expressed with
NR1-1a. Inactivation was normal for NR2Astop1029
(44.9 ± 3.6%; n = 5),
NR2Astop905 (46.5 ± 3.6%;
n = 9), and NR2Astop874 (Fig.
6A). As expected for a process dependent
on calcium influx, inactivation was absent at positive holding
potentials. In contrast, responses from
NR2Astop844 showed a prominent relaxation not
only at a holding potential of
50 mV but also at +50 mV (Fig. 6A). Likewise, when coexpressed with NR1stop838, a
construct that prevents inactivation, a relaxation of ~40% was
present at all holding potentials in
NR1stop838/2Astop844 but
not NR1stop838/2Astop874 (Fig. 6A).
|
| |
Discussion |
|---|
|
|
|---|
Complexity of NMDA Channel Structure and Function.
Our results
show that multiple structural elements contribute to the NR2-subunit
specificity of inactivation. This highlights the impact of the complex
structure of large proteins such as the NMDA channel on their function.
Such complexity is also evident from studies of receptor properties
that might be expected to be confined to a single domain. The
structural determinants responsible for NMDA channel block by
extracellular magnesium are a case in point. The main determinants for
extracellular magnesium block are within the pore-forming M2-loop of
all NR2 subunits (Burnashev et al., 1992
; Mori et al., 1992
; Sakurada
et al., 1993
; Williams et al., 1998
; Wollmuth et al., 1998
). However,
three NR2 regions outside of M2 modulate the efficacy of extracellular
magnesium (Kuner and Schoepfer, 1996
) and complicate the picture
substantially. Even a combined exchange of these regions in NR2C for
NR2B is insufficient to produce magnesium block identical to NR2B,
indicating that small structural differences outside the pore affect
the channel. A similar conclusion has been reached by studies of single point mutations in the NR1 subunit (Kawajiri and Dingledine, 1993
). It
is not surprising that a similar complexity prevails when the molecular
structures associated with the dynamics of channel gating are studied.
Calcium-Dependent Inactivation and Calcium Permeability:
Coexistence or Codependence?
Our results show that the M2-3 loop
affects two prominent features of the NMDA channel: calcium
permeability and calcium-dependent inactivation. Thus, both
characteristics could be related functionally and structurally.
Although calcium influx through NMDA channels is a prerequisite for
calcium-dependent inactivation (Legendre et al., 1993
; Krupp et al.,
1996
), the modulation of both characteristics does not covary with the
NR2-subunit. For example, the calcium permeability of NR1/2C heteromers
is only 30% lower than NR1/2A heteromers (Burnashev et al., 1995
), yet
expression of NR2C completely prevents inactivation by a mechanism that
cannot be explained by changes in calcium influx (Krupp et al., 1996
).
In addition, the calcium-permeability of NR1/2A and NR1/2B is slightly
higher than NR1/2C and NR1/2D (Monyer et al., 1992
, 1994
). In contrast, calcium-dependent inactivation occurs in NR1/2A, NR1/2D, and possibly NR1/2B but is absent in NR1/2C (Medina et al., 1995
; Krupp et al.,
1996
). Our findings provide an explanation for the lack of correlation
between calcium permeability and calcium-dependent inactivation. A
residue that affects calcium permeability (residue 620 in NR2A) is a
glutamine in NR2A and NR2B, but a glutamate in NR2C and NR2D. Likewise,
the position that codetermines the NR2-subunit specificity of
inactivation (residue 619 of NR2A) is a valine in NR2A, NR2B, and NR2D,
but an isoleucine in NR2C.
Inactivation and the Role of the M2-3 Loop of NR2.
Our
results show that several residues in the M2-3 loop of NR2 affect
inactivation, including the threonine and serine residues at position
625-627. These residues could in principle be phosphorylated. We did
find reduced inactivation in some of the relevant mutants after
inhibition of staurosporine-sensitive kinases or casein kinase II.
Whereas the two threonines at positions 625 and 626, as well as serine
627, are within good recognition sequences for several
staurosporine-sensitive kinases (Kemp and Pearson, 1990
), the M2-3
loop of NR2 does not contain a casein kinase II recognition sequence
(Guerra et al., 1999
). It is also not clear whether phosphorylation of
any of the three residues is indeed involved in the effects seen with
the kinase inhibitors. However, it is certainly plausible that
phosphorylation could affect inactivation. For example, casein kinase
II affects the open probability of NMDA channels (Lieberman and Mody,
1999
), and protein kinase C can increase inactivation in hippocampal
neurons, possibly by regulating the efficiency of receptor interactions
with intracellular proteins like calcium/calmodulin or
-actinin (Lu
et al., 2000
). Because we used the NR1-4a subunit, phosphorylation of
the C1-exon of NR1 (Tingley et al., 1997
) was not a factor in our experiments.
++++
) is nearly a negative mirror (+n

+)
of the C-terminal part (underlined) of the M2-3 loop of NR2A
(VQNPKGTTSK), raising the possibility of an
interaction of both regions.
Implications for Synaptic Transmission.
Calcium-dependent
inactivation provides a mechanism for activity-dependent regulation of
synaptic NMDA receptors. The slow kinetics of inactivation in
whole-cell recordings might seem to indicate that it does not play a
role during fast excitatory transmission. However, inactivation is
present at synapses, presumably because local rapid accumulations of
calcium are sufficient (Rosenmund et al., 1995
; Umemiya et al., 2001
).
Although most synapses contain both NMDA and AMPA receptors,
inactivation may be particularly important under conditions in which
the NMDA receptors dominate. The present results add to the existing
evidence that not only calcium influx, but also interactions between
subunits and with regulatory proteins, such as calmodulin and
-actinin, are involved in the inactivation process.
| |
Footnotes |
|---|
Received August 30, 2001; Accepted November 29, 2001
This work was supported by National Institutes of Health grants MH46613 (G.L.W.), NS28709 (S.F.H.), the McKnight Foundation (S.F.H.), the John Adler Foundation (S.F.H.), fellowships from the Human Frontiers program (J.J.K. and B.V.), a Bundy Foundation award (B.V.) and a CJ Martin NHMRC of Australia award (B.V.). B.V. and J.J.K. contributed equally to this work.
Dr. Johannes J. Krupp, AstraZeneca R&D Södertälje, NOVUM, Hälsovägen 7, 14157 Huddinge, Sweden. E-mail: johannes.krupp{at}astrazeneca.com
| |
Abbreviations |
|---|
NMDA, N-methyl-D-aspartate;
NR, N-methyl-D-aspartate receptor;
HEK, human
embryonic kidney;
Mx, membrane region, where
x is 1, 2, or 3;
DRB, 5,6-dichloro-1-
-D-ribofuranosylbenzimidazole.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Petrovic, M. Sedlacek, M. Horak, H. Chodounska, and L. Vyklicky Jr 20-Oxo-5{beta}-Pregnan-3{alpha}-yl Sulfate Is a Use-Dependent NMDA Receptor Inhibitor J. Neurosci., September 14, 2005; 25(37): 8439 - 8450. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Sobolevsky, L. Rooney, and L. P. Wollmuth Staggering of Subunits in NMDAR Channels Biophys. J., December 1, 2002; 83(6): 3304 - 3314. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||